Solasta Ventures

Solasta Ventures is a venture capital firm dedicated to investing in innovative companies that aim to improve the standard of care for diseases with unmet medical needs. The firm leverages deep scientific expertise and an extensive network to identify promising therapeutics and discovery platforms with the potential to transform patients' lives worldwide. As a wholly-owned subsidiary of Aju IB Investment, a leading South Korean venture capital firm, Solasta Ventures bridges geographies to drive potential U.S.-Korea synergies.

The firm's investment focus includes therapeutics and technology that transform care for patients in U.S. and global markets, strong management teams capable of efficiently utilizing capital, and the potential for partnerships and collaborations with global pharmaceutical companies, including those in their South Korean network. Solasta Ventures seeks to proactively support pioneers at the forefront of the rapidly evolving life sciences space.

With a team boasting over 30 years of combined experience in healthcare investments and drug development, Solasta Ventures has been involved in several notable investments. These include a $72 million Series A financing for Maxion Therapeutics, co-led by General Catalyst and supported by Solasta Ventures, Eli Lilly and Company, and others. The financing aims to advance Maxion's innovative platform for developing medicines targeting ion channels and G protein-coupled receptors. Additionally, Solasta Ventures has supported Axonis Therapeutics in raising $115 million in Series A financing to develop novel neuromedicines targeting KCC2, co-led by Cormorant Asset Management, LP and venBio, with significant investments from Sofinnova Investments, MRL Ventures Fund LLC, Perceptive Advisors, and others. These investments underscore Solasta Ventures' commitment to advancing medicine and improving patient outcomes.

Solasta Ventures is headquartered in Boston, Massachusetts, and maintains a strong presence in South Korea, leveraging its parent company's network to foster international collaborations and synergies in the life sciences sector. The firm's strategic approach and extensive experience position it as a significant player in the venture capital landscape, dedicated to supporting the next generation of transformative healthcare innovations.